CollPlant Biotechnologies Ltd. (CLGN)
NASDAQ: CLGN · IEX Real-Time Price · USD
6.19
+0.31 (5.37%)
At close: May 2, 2024, 4:00 PM
6.45
+0.27 (4.28%)
After-hours: May 2, 2024, 7:32 PM EDT
CollPlant Biotechnologies Revenue
In the year 2023, CollPlant Biotechnologies had annual revenue of $10.96M with 3,565.22% growth. Revenue in the quarter ending December 31, 2023 was $299.00K with 415.52% year-over-year growth.
Revenue (ttm)
$10.96M
Revenue Growth
+3,565.22%
P/S Ratio
6.46
Revenue / Employee
$146,120
Employees
75
Market Cap
70.85M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 10.96M | 10.66M | 3,565.22% |
Dec 31, 2022 | 299.00K | -15.34M | -98.09% |
Dec 31, 2021 | 15.64M | 9.50M | 154.86% |
Dec 31, 2020 | 6.14M | 3.82M | 164.75% |
Dec 31, 2019 | 2.32M | -2.70M | -53.77% |
Dec 31, 2018 | 5.01M | 4.55M | 982.94% |
Dec 31, 2017 | 463.00K | 381.82K | 470.37% |
Dec 31, 2016 | 81.18K | - | - |
Dec 31, 2015 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
MDxHealth | 70.19M |
Champions Oncology | 49.22M |
Cryo-Cell International | 31.37M |
Carisma Therapeutics | 14.92M |
Celularity | 14.79M |
Asensus Surgical | 8.58M |
CLGN News
- 4 weeks ago - COLLPLANT BIOTECHNOLOGIES REPORTS 2023 FULL YEAR FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE - PRNewsWire
- 5 weeks ago - COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR 2023 FULL YEAR FINANCIAL RESULTS AND CONFERENCE CALL INFORMATION - PRNewsWire
- 2 months ago - CollPlant Issues Letter to Shareholders - PRNewsWire
- 4 months ago - CollPlant's CEO to Present at the Octane Aesthetic Tech Forum Conference, in Newport Beach, California - PRNewsWire
- 4 months ago - CollPlant Biotechnologies Begins Preclinical Trial with Commercial-Size, Regenerative Breast Implants - PRNewsWire
- 5 months ago - CollPlant Biotechnologies Announces Third Quarter Financial Results for 2023 - PRNewsWire
- 6 months ago - COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR 2023 THIRD QUARTER FINANCIAL RESULTS AND CONFERENCE CALL INFORMATION - PRNewsWire
- 6 months ago - CollPlant Biotechnologies Announces Patent Granted in U.S. for Photocurable Dermal Filler - PRNewsWire